Clinical trial
A Phase II Trial of Autologous Ex Vivo Expanded Tumor-Infiltrating Lymphocyte (TIL) Therapy With Lifileucel After Failure of PD-1 Blockade in Kidney Cancer.
NCT07925333 is registered in ClinicalTrials.gov with Beth Israel Deaconess Medical Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Trial of Autologous Ex Vivo Expanded Tumor-Infiltrating Lymphocyte (TIL) Therapy With Lifileucel After Failure of PD-1 Blockade in Kidney Cancer.
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- April 26, 2027
- Completion date
- March 1, 2030
- Enrollment
- 10 (estimated)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.
kidney cancers, renal cell carcinoma (kidney cancer)
Arms
As registered; 1 arm.
-
Lifileucel (LN-145) TIL regimen
Participants undergo tumor resection for TIL manufacturing, then receive lymphodepleting cyclophosphamide and fludarabine, followed byLN-145/lifileucel infusion and IL-2 (aldesleukin), with scheduled post-treatment clinic visits and long-term follow-up
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Radiographic Objective Response Rate
HCC-centrally assessed Objective Response Rate per RECIST 1.1 of the efficacy evaluable population Primary analysis is performed on patients who receive TIL.
Lead sponsor's other trials
Beth Israel Deaconess Medical Center, most recent start first.
+562 more trials See the organization page
Similar trials
Same condition (Carcinoma, Renal Cell) and phase, most recent start first.
+593 more trials See the condition page